Abstract
Contemporary treatment of multiple cerebrospinal sclerosis is not causal and influences mainly only its immunopathogenetic mechanisms and as a result, it only reduces and slows down the demyelization process and loss of axons of the central nervous system (CNS). This has lead to an unceasing search for a new immunotherapy that might change the balance of the immune system and be applicable to affect the autoimmune mechanisms.
Research of monoclonal antibodies may be promising in this direction.